Rajkumar Savai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7917388/publications.pdf

Version: 2024-02-01

		19657	19749
167	14,718	61	117
papers	citations	h-index	g-index
170	170	170	15349
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157.	27.0	2,237
2	Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 2005, 115, 2811-2821.	8.2	917
3	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
4	Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology, 2011, 8, 443-455.	13.7	605
5	Real-time quantitative RT–PCR after laser-assisted cell picking. Nature Medicine, 1998, 4, 1329-1333.	30.7	547
6	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
7	Imatinib for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 1412-1413.	27.0	440
8	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1171-1177.	5.6	331
9	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 897-908.	5 . 6	296
10	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	28.9	293
11	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19093-19098.	7.1	273
12	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nature Medicine, 2014, 20, 1289-1300.	30.7	233
13	Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 2017, 8, 48436-48452.	1.8	216
14	S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL- $1\hat{l}^2$. Journal of Experimental Medicine, 2017, 214, 2695-2713.	8.5	216
15	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 409-419.	5 . 6	206
16	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. Circulation, 2017, 136, 65-79.	1.6	196
17	Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 437-447.	5.6	186
18	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radical Biology and Medicine, 2004, 36, 1279-1288.	2.9	183

#	Article	IF	CITATIONS
19	Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension. Journal of Immunology, 2014, 193, 597-609.	0.8	162
20	Tumor-derived exosomes in the regulation of macrophage polarization. Inflammation Research, 2020, 69, 435-451.	4.0	153
21	Phytochemicals as modulators of M1-M2 macrophages in inflammation. Oncotarget, 2018, 9, 17937-17950.	1.8	143
22	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. Circulation, 2008, 118, 2081-2090.	1.6	139
23	Targeting cancer with phosphodiesterase inhibitors. Expert Opinion on Investigational Drugs, 2010, 19, 117-131.	4.1	123
24	Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene, 2013, 32, 1121-1134.	5.9	120
25	Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery, 2010, 9, 956-970.	46.4	118
26	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	5 . 6	118
27	T <scp>ranslational</scp> A <scp>dvances in the</scp> F <scp>ield of</scp> P <scp>ulmonary</scp> H <scp>ypertension</scp> .From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. American Journal of Respiratory and Critical Care Medicine. 2017. 195. 425-437.	5. 6	117
28	Reprogramming of tumor-associated macrophages by targeting \hat{l}^2 -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. Science Advances, 2020, 6, eaaz6105.	10.3	110
29	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non–Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4414-4425.	0.9	109
30	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1354-1365.	2.4	108
31	Heterogeneity in Lung ¹⁸ FDG Uptake in Pulmonary Arterial Hypertension. Circulation, 2013, 128, 1214-1224.	1.6	107
32	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax, 2015, 70, 1022-1032.	5 . 6	106
33	Hypoxia-inducible factor signaling in pulmonary hypertension. Journal of Clinical Investigation, 2020, 130, 5638-5651.	8.2	104
34	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. Journal of Clinical Investigation, 2020, 130, 3560-3575.	8.2	103
35	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. PLoS ONE, 2015, 10, e0139073.	2.5	101
36	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	2.5	100

#	Article	IF	CITATIONS
37	The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 683-691.	2.9	93
38	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1137-1149.	6.7	89
39	Role of Hypoxia-Inducible Factor-1α in Hypoxia-Induced Apoptosis of Primary Alveolar Epithelial Type II Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 395-403.	2.9	87
40	Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. Neoplasia, 2009, 11, 48-56.	5.3	87
41	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Molecular Medicine, 2018, 10, 276-293.	6.9	85
42	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. Molecular Biology of the Cell, 2009, 20, 4751-4765.	2.1	84
43	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 188-196.	5.6	82
44	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke–induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
45	Increased Protein Arginine Methylation in Chronic Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 436-443.	2.9	78
46	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 373-385.	5.6	78
47	A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension. Nature Communications, 2019, 10, 2130.	12.8	77
48	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. Frontiers in Oncology, 2020, 10, 324.	2.8	76
49	cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue. American Journal of Pathology, 2002, 160, 81-90.	3.8	75
50	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	5.6	75
51	Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis. PLoS ONE, 2013, 8, e79798.	2.5	75
52	CRISPR-Cas9–based target validation for p53-reactivating model compounds. Nature Chemical Biology, 2016, 12, 22-28.	8.0	74
53	Hypoxiaâ€driven proliferation of human pulmonary artery fibroblasts: crossâ€ŧalk between HIFâ€1α and an autocrine angiotensin system. FASEB Journal, 2005, 19, 1-26.	0.5	72
54	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	2.9	72

#	Article	IF	Citations
55	Lung cancer–associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell–immune cell cross-talk. Science Translational Medicine, 2017, 9, .	12.4	69
56	The rapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. Frontiers in Immunology, 2019, 10, 1808.	4.8	69
57	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	12.8	69
58	Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. British Journal of Pharmacology, 2021, 178, 54-71.	5.4	69
59	RNA interference for HIF- $1\hat{l}\pm$ inhibits its downstream signalling and affects cellular proliferation. Biochemical and Biophysical Research Communications, 2003, 312, 571-577.	2.1	68
60	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 358-367.	2.9	66
61	Amplified canonical transforming growth factor \hat{l}^2 signalling <i>via</i> heat shock protein 90 in pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1501941.	6.7	66
62	Potential Applications of Flat-Panel Volumetric CT in Morphologic, Functional Small Animal Imaging. Neoplasia, 2005, 7, 730-740.	5.3	63
63	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
64	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. Antioxidants and Redox Signaling, 2013, 19, 2213-2231.	5.4	62
65	Zyxin Is a Transforming Growth Factor- \hat{l}^2 (TGF- \hat{l}^2)/Smad3 Target Gene That Regulates Lung Cancer Cell Motility via Integrin $\hat{l}\pm5\hat{l}^21$. Journal of Biological Chemistry, 2012, 287, 31393-31405.	3.4	61
66	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, 2011, 03, 87ra53.	12.4	59
67	Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 47-57.	2.9	59
68	Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunology, Immunotherapy, 2014, 63, 1297-1306.	4.2	58
69	PDGF Receptor and its Antagonists: Role in Treatment of PAH. Advances in Experimental Medicine and Biology, 2010, 661, 435-446.	1.6	55
70	miR-223–IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovascular Research, 2016, 111, 184-193.	3.8	54
71	Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nature Communications, 2019, 10, 2229.	12.8	53
72	Impact of HIFâ€1α and HIFâ€2α on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. FASEB Journal, 2006, 20, 163-165.	0.5	52

#	Article	IF	CITATIONS
73	S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. Journal of Clinical Investigation, 2020, 130, 5461-5476.	8.2	48
74	Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 611-619.	5.6	46
75	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 41.	2.0	46
76	Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1720-1723.	8.2	46
77	Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunology, Immunotherapy, 2013, 62, 309-320.	4.2	45
78	Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. Journal of Experimental Medicine, 2019, 216, 1377-1395.	8.5	45
79	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer, 2021, 153, 150-157.	2.0	45
80	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. Circulation, 2011, 123, 1194-1204.	1.6	42
81	Targeting Jak–Stat Signaling in Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 100-114.	2.9	37
82	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2014, 4, 128-136.	1.7	36
83	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637.	1.7	35
84	Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets. Frontiers in Pharmacology, 2018, 9, 1201.	3.5	35
85	Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. European Respiratory Journal, 2022, 59, 2002248.	6.7	35
86	Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunology, Immunotherapy, 2017, 66, 799-809.	4.2	33
87	Analysis of Tumor Vessel Supply in Lewis Lung Carcinoma in Mice by Fluorescent Microsphere Distribution and Imaging with Micro- and Flat-Panel Computed Tomography. American Journal of Pathology, 2005, 167, 937-946.	3.8	32
88	The emerging role of epigenetics in pulmonary hypertension. European Respiratory Journal, 2016, 48, 903-917.	6.7	32
89	Cell Density Regulates Neutrophil IL-8 Synthesis: Role of IL-1 Receptor Antagonist and Soluble TNF Receptors. Journal of Immunology, 2001, 166, 6287-6293.	0.8	30
90	Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opinion on Investigational Drugs, 2012, 21, 1107-1122.	4.1	30

#	Article	IF	Citations
91	miRâ€574â€5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGESâ€1 induction. FASEB Journal, 2019, 33, 6933-6947.	0.5	30
92	Nonâ€invasive lung cancer diagnosis by detection of <i><scp>GATA</scp>6</i> and <i><scp>NKX</scp>2â€1</i> isoforms in exhaled breath condensate. EMBO Molecular Medicine, 2016, 8, 1380-1389.	6.9	29
93	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS ONE, 2015, 10, e0129327.	2.5	29
94	A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells. Cancer Research, 2007, 67, 5443-5453.	0.9	26
95	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology, 2019, 9, 1550.	2.8	26
96	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. European Respiratory Journal, 2019, 53, 1802445.	6.7	25
97	Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. European Respiratory Review, 2020, 29, 200134.	7.1	25
98	Identification of tumorâ€associated macrophage subsets that are associated with breast cancer prognosis. Clinical and Translational Medicine, 2020, 10, e239.	4.0	25
99	E-cadherin Controls Bronchiolar Progenitor Cells and Onset of Preneoplastic Lesions in Mice. Neoplasia, 2012, 14, 1164-IN31.	5.3	24
100	ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Scientific Reports, 2014, 4, 6899.	3.3	24
101	Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. Analytical and Bioanalytical Chemistry, 2008, 390, 697-714.	3.7	23
102	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. Circulation, 2014, 129, 1510-1523.	1.6	23
103	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
104	Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. Scientific Reports, 2018, 8, 12471.	3.3	22
105	Small extracellular vesicleâ€derived miRâ€574â€5p regulates PGE2â€biosynthesis via TLR7/8 in lung cancer. Journal of Extracellular Vesicles, 2021, 10, e12143.	12.2	21
106	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. Circulation, 2022, 145, 916-933.	1.6	21
107	Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunology, Immunotherapy, 2013, 62, 1283-1292.	4.2	19
108	Phenotypic Plasticity of Fibroblasts during Mammary Carcinoma Development. International Journal of Molecular Sciences, 2019, 20, 4438.	4.1	19

#	Article	IF	Citations
109	Macrophage Regulation during Vascular Remodeling: Implications for Pulmonary Hypertension Therapy. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 556-558.	2.9	18
110	Maintained right ventricular pressure overload induces ventricular–arterial decoupling in mice. Experimental Physiology, 2017, 102, 180-189.	2.0	18
111	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. British Journal of Pharmacology, 2021, 178, 31-53.	5.4	18
112	Nintedanib in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 808-810.	5.6	17
113	Epithelial cell plasticity defines heterogeneity in lung cancer. Cellular Signalling, 2020, 65, 109463.	3.6	17
114	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. International Journal of Molecular Sciences, 2022, 23, 546.	4.1	16
115	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Science Translational Medicine, 2022, 14 , .	12.4	15
116	Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 163-170.	2.9	14
117	Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. Scientific Reports, 2017, 7, 3896.	3.3	14
118	$3\hat{a}\in^2$ -Deoxy- $3\hat{a}\in^2$ -[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circulation: Cardiovascular Imaging, 2018, 11, e007402.	2.6	14
119	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. Cancers, 2020, 12, 3528.	3.7	13
120	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. European Respiratory Journal, 2022, 59, 2101153.	6.7	13
121	Amplification of Lipopolysaccharide-Induced Cytokine Synthesis in Non–Small Cell Lung Cancer/Neutrophil Cocultures. Molecular Cancer Research, 2009, 7, 1729-1735.	3.4	12
122	Depletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice. Cells, 2019, 8, 1210.	4.1	12
123	Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas. Cells, 2020, 9, 1755.	4.1	12
124	Disrupted PI3K subunit p $110\hat{l}\pm$ signaling protects against pulmonary hypertension and reverses established disease in rodents. Journal of Clinical Investigation, 2021, 131, .	8.2	12
125	Adenylate Kinase 4—A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1α Signaling Pathways. International Journal of Molecular Sciences, 2021, 22, 10371.	4.1	11
126	Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation. Cancer Research, 2022, 82, 1617-1632.	0.9	11

#	Article	IF	Citations
127	Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. Translational Oncology, 2014, 7, 702-711.	3.7	10
128	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. Circulation: Cardiovascular Imaging, 2018, 11, e007653.	2.6	10
129	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers, 2021, 13, 208.	3.7	10
130	Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis. Cancer Research, 2022, 82, 1380-1395.	0.9	10
131	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2011, 20, 61-74.	4.1	9
132	Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth. Journal of Biological Chemistry, 2014, 289, 26804-26816.	3.4	9
133	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16.	1.7	9
134	Metastasis-Associated Protein 2 Represses NF-κB to Reduce Lung Tumor Growth and Inflammation. Cancer Research, 2020, 80, 4199-4211.	0.9	9
135	Epigenetic Regulation by <i>Suv4-20h1</i> in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Circulation, 2021, 144, 1042-1058.	1.6	9
136	Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. Cardiovascular Research, 2022, 118, 305-315.	3.8	8
137	Non-invasive screening of lung nodules in mice comparing a novel volumetric computed tomography with a clinical multislice CT. Oncology Reports, 2007, 17, 707-12.	2.6	8
138	IRAG1 Deficient Mice Develop PKG1 \hat{l}^2 Dependent Pulmonary Hypertension. Cells, 2020, 9, 2280.	4.1	7
139	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. Cancers, 2021, 13, 4127.	3.7	7
140	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132.	2.4	7
141	Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1316-1319.	5.6	6
142	Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget, 2018, 9, 28976-28988.	1.8	6
143	Depletion of Numb and Numblike in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the \hat{I}^2 -Catenin Signaling Pathway. Frontiers in Cell and Developmental Biology, 2021, 9, 639162.	3.7	5
144	Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry. Frontiers in Immunology, 2022, 13, 827719.	4.8	5

#	Article	IF	CITATIONS
145	Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. Cells, 2022, 11, 2121.	4.1	5
146	Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452.	5.6	4
147	Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1502.	4.1	4
148	On the origin of germ cell neoplasia in situ: Dedifferentiation of human adult Sertoli cells in cross talk with seminoma cells in vitro. Neoplasia, 2021, 23, 731-742.	5.3	4
149	Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice. PLoS ONE, 2011, 6, e29093.	2.5	3
150	Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 941-943.	5.6	3
151	Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. International Journal of Environmental Research and Public Health, 2021, 18, 8280.	2.6	3
152	A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 723-724.	2.9	1
153	Abstract 1594: Contribution of Stromal Lymphocytes to Lung Cancer Metastasis: Role in Epithelial Mesenchymal Transition. , 2016, , .		1
154	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Global Cardiology Science & Practice, 2020, 2020, e202010.	0.4	1
155	Drug repositioning as an effective therapy for proteaseâ€activated receptor 2 inhibition. Journal of Cellular Biochemistry, 2019, 120, 1522-1526.	2.6	0
156	Reply to: Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1113.	5.6	0
157	Abstract 2604: Involvement of circulating fibrocytes in the progression of adenocarcinomas by modulating EMT and tumor microenvironment , 2013, , .		0
158	Abstract 4681: Characterization of pulmonary hypertension in lung cancer, 2013,,.		0
159	RASSF1A regulates ROS-HIF axis in hypoxia driven pulmonary hypertension. , 2016, , .		O
160	LSC Abstract $\hat{a} \in \text{``Histone}$ deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer. , 2016, , .		0
161	Abstract 944: Chemokine receptor signaling as a new tool to improve lung cancer diagnostics and therapy. , $2017, , .$		0
162	Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancer. , 2017, , .		0

#	Article	lF	CITATIONS
163	Proangiogenic and wound healing molecular and histological fingerprint of chronic thromboembolic pulmonary hypertension. , 2017, , .		O
164	LSC - 2017 - Reprogramming Of Tumor Associated Macrophages By Modulating Wnt/ $\tilde{\rm A}\ddot{\rm Y}$ -catenin Signalling In Lung Cancer. , 2017, , .		0
165	Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. , $2017, , .$		O
166	Histone Deacetylase 7 regulates master transcription factors and modulates mitochondrial function. , $2017, \dots$		0
167	LncRNAs: Emerging Regulators of PDGF Signaling. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	2.9	0